Cutler Group’s Vivos Therapeutics VVOS Stock Holding History

Cutler Group’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-764	Closed	-$2K	–	6166
2021 Q3	$2K	Buy	+764	New	+$80.3K	﹤0.01%	5123

Other funds holding VVOS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's VVOS Position: Q1 2024 in Review

Cutler Group sold out of Vivos Therapeutics (VVOS) in Q1 2024, closing a stake of 12 shares.

Cutler Group first reported a position in VVOS in Q3 2021 and held it in 5 quarters. The position peaked at $3K in Q2 2023. 16 funds tracked by Wall St. Rank hold VVOS as of Q1 2024.

Cutler Group reported no remaining Vivos Therapeutics position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 12 Vivos Therapeutics shares in Q1 2024.
Cutler Group first reported a position in Vivos Therapeutics in Q3 2021 and held it in 5 quarters.
Cutler Group's Vivos Therapeutics position peaked at $3K in Q2 2023.
16 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.